Date published: 2025-11-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

MFRP Inhibitors

MFRP inhibitors, short for Membrane-Type Frizzled-Related Protein inhibitors, represent a class of chemical compounds that exert their effects on a specific cellular pathway involved in signal transduction and regulation. These inhibitors target the Membrane-Type Frizzled-Related Protein, or MFRP, which plays a crucial role in modulating cellular responses to extracellular signals, particularly those mediated by the Frizzled family of receptors. Frizzled receptors are integral components of the Wnt signaling pathway, a highly conserved and complex network that governs various biological processes, including embryonic development, tissue homeostasis, and cell proliferation. MFRP inhibitors, by interfering with the function of MFRP, can impact the Wnt signaling cascade and consequently influence a wide array of cellular activities.

The mechanism of action of MFRP inhibitors primarily involves the disruption of MFRP's interaction with Frizzled receptors, hindering the formation of functional signaling complexes. This disruption can occur at multiple points within the pathway, such as inhibiting the binding of MFRP to Frizzled receptors or blocking downstream signaling events. By interfering with this signaling pathway, MFRP inhibitors have to influence cell fate determination, tissue regeneration, and even tumorigenesis in various organisms. The development and study of MFRP inhibitors are of particular interest in the field of molecular biology and pharmacology, as they provide valuable insights into the intricate mechanisms governing cellular behavior and may hold promise for future applications in the realm of targeted interventions in a variety of contexts.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib mesylate

220127-57-1sc-202180
sc-202180A
25 mg
100 mg
$44.00
$109.00
61
(1)

Imatinib inhibits tyrosine kinase activity, specifically targeting the BCR-ABL fusion protein, which is associated with chronic myeloid leukemia (CML).

Tamoxifen

10540-29-1sc-208414
2.5 g
$256.00
18
(2)

Tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, inhibiting their activation. It's used for estrogen receptor-positive breast cancer by blocking estrogen's proliferative effects.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib inhibits multiple kinases involved in tumor growth and angiogenesis, including Raf kinases and VEGFR-2. It disrupts cancer cell signaling pathways, hindering tumor progression.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

Everolimus inhibits mTOR (mammalian target of rapamycin) signaling, disrupting cell growth and proliferation.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks EGFR activation, suppressing tumor cell division, and is used in lung cancer therapy.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Vemurafenib targets the mutated BRAF kinase in melanoma. It inhibits the MAPK pathway, reducing cell proliferation and promoting apoptosis in BRAF-mutated melanoma cells.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib inhibits the proteasome, blocking the breakdown of ubiquitinated proteins and causing cell cycle arrest and apoptosis.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor studied in the research of B-cell malignancies. It disrupts B-cell receptor signaling and inhibits cancer cell survival.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib is a MEK1/2 inhibitor that blocks the MAPK signaling pathway in cancer cells. It's used in melanoma and non-small cell lung cancer therapy.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib inhibits multiple kinases, including BCR-ABL and Src family kinases.